MedPath

Effect of Oral and Injectable Risperidone on Prolactin in Psychotic Patients

Phase 3
Recruiting
Conditions
The effect of oral and injectable risperidone on serum prolactin level.
Registration Number
IRCT20221003056082N1
Lead Sponsor
niversity of social welfare and rehabilitation sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Age 18 to 60 years
Having a psychotic disorder
No mood disorder
A candidate for antipsychotics
Not using antipsychotic drugs in the last year
Patient satisfaction and cooperation

Exclusion Criteria

Patients with high prolactin levels
Patients with hypothyroidism
Patients with impaired liver or kidney tests
Pregnant women

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum prolactin level. Timepoint: Before starting the treatment and on the first day, the seventh day and the fourteenth day after starting the treatment with oral or injectable risperidone. Method of measurement: Prolactin laboratory kit.
Secondary Outcome Measures
NameTimeMethod
Fasting blood sugar. Timepoint: Before the intervention and on the fourteenth day after the intervention. Method of measurement: Blood sugar laboratory kit.;Blood triglycerides. Timepoint: Before the intervention and on the fourteenth day after the intervention. Method of measurement: Triglyceride laboratory kit.;Blood cholesterol. Timepoint: Before the intervention and on the fourteenth day after the intervention. Method of measurement: Cholesterol laboratory kit.
© Copyright 2025. All Rights Reserved by MedPath